Suggested remit - To appraise the clinical and cost effectiveness of ropeginterferon alfa-2b within its marketing authorisation for treating polycythaemia vera without symptomatic splenomegaly
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 1596
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 July 2023 | Note - Note added to the project documents |
| 16 January 2020 | Note added to the project documents |
| 27 June 2019 | Note added to the project documents |
| 17 May 2019 - 17 June 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 09 May 2019 | In progress. Referred 29 April 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual